相似文献
1
Tumour necrosis factor in synovial exudates.
Ann Rheum Dis. 1988 Sep;47(9):768-72. doi: 10.1136/ard.47.9.768.
2
Role of TNF alpha in the induction of antigen induced arthritis in the rabbit and the anti-arthritic effect of species specific TNF alpha neutralising monoclonal antibodies.
Ann Rheum Dis. 1995 May;54(5):366-74. doi: 10.1136/ard.54.5.366.
3
Tumour necrosis factor activity in joint fluids from rheumatoid arthritis patients.
Br J Rheumatol. 1989 Apr;28(2):104-8. doi: 10.1093/rheumatology/28.2.104.
4
Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases.
Arthritis Rheum. 1992 Oct;35(10):1160-9. doi: 10.1002/art.1780351008.
5
Metalloproteinases and tumor necrosis factor-alpha activities in synovial fluids of horses: correlation with articular cartilage alterations.
Vet Res. 2000 Sep-Oct;31(5):507-15. doi: 10.1051/vetres:2000136.
6
Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis.
Ann Rheum Dis. 1990 Sep;49(9):665-7. doi: 10.1136/ard.49.9.665.
7
Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum.
Arthritis Rheum. 1988 Aug;31(8):1041-5. doi: 10.1002/art.1780310816.
8
Cytokines in synovial fluid: II. The presence of tumour necrosis factor and interferon.
Clin Exp Immunol. 1988 Jul;73(1):88-92.
9
Characteristics of tumor necrosis factor production in rheumatoid arthritis.
Cell Immunol. 1989 Aug;122(1):131-45. doi: 10.1016/0008-8749(89)90154-8.
10
Tumor necrosis factor in synovial fluid of patients with temporomandibular disorders.
J Oral Maxillofac Surg. 1995 Apr;53(4):424-6. doi: 10.1016/0278-2391(95)90717-3.
引用本文的文献
1
Novel peptide inhibitor of human tumor necrosis factor-α has antiarthritic activity.
Sci Rep. 2024 Jun 5;14(1):12935. doi: 10.1038/s41598-024-63790-6.
2
Efficacy and Safety of CMAB008 Compared with Innovator Infliximab in Patients with Moderate-to-Severe Rheumatoid Arthritis Receiving Concomitant Methotrexate: A Randomized, Double-blind, Multi-center, Phase III Non-inferiority Study.
Rheumatol Ther. 2023 Jun;10(3):757-773. doi: 10.1007/s40744-023-00544-2. Epub 2023 Mar 25.
3
JAK inhibitors differentially modulate B cell activation, maturation and function: A comparative analysis of five JAK inhibitors in an B cell differentiation model and in patients with rheumatoid arthritis.
Front Immunol. 2023 Jan 26;14:1087986. doi: 10.3389/fimmu.2023.1087986. eCollection 2023.
4
Recent Advances in Understanding the Pathogenesis of Rheumatoid Arthritis: New Treatment Strategies.
Cells. 2021 Nov 4;10(11):3017. doi: 10.3390/cells10113017.
5
Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts.
Front Immunol. 2021 Oct 27;12:672255. doi: 10.3389/fimmu.2021.672255. eCollection 2021.
6
Internalization of Neutrophil-Derived Microvesicles Modulates TNFα-Stimulated Proinflammatory Cytokine Production in Human Fibroblast-Like Synoviocytes.
Int J Mol Sci. 2021 Jul 10;22(14):7409. doi: 10.3390/ijms22147409.
7
Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis.
Front Immunol. 2021 Apr 6;12:638444. doi: 10.3389/fimmu.2021.638444. eCollection 2021.
8
Autoantibodies Targeting Intracellular and Extracellular Proteins in Autoimmunity.
Front Immunol. 2021 Mar 8;12:548469. doi: 10.3389/fimmu.2021.548469. eCollection 2021.
9
Cytokine-regulated Th17 plasticity in human health and diseases.
Immunology. 2021 May;163(1):3-18. doi: 10.1111/imm.13280. Epub 2020 Nov 6.
10
Synovial Cell Migration is Associated with B Cell Activating Factor Expression Increased by TNFα or Decreased by KR33426.
Biomol Ther (Seoul). 2020 Sep 1;28(5):405-413. doi: 10.4062/biomolther.2020.110.
本文引用的文献
1
Isolation of an interleukin-1-like factor from human joint effusions.
Arthritis Rheum. 1983 Aug;26(8):975-83. doi: 10.1002/art.1780260806.
2
Malarial parasites and tumour cells are killed by the same component of tumour necrosis serum.
Clin Exp Immunol. 1984 Aug;57(2):293-300.
3
Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon.
Proc Natl Acad Sci U S A. 1983 Sep;80(17):5397-401. doi: 10.1073/pnas.80.17.5397.
4
Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors.
J Immunol. 1985 Sep;135(3):2069-73.
5
Release of interleukin-1 from human synovial tissue in vitro.
Arthritis Rheum. 1985 Aug;28(8):853-62. doi: 10.1002/art.1780280804.
6
Human tumor necrosis factor. Production, purification, and characterization.
J Biol Chem. 1985 Feb 25;260(4):2345-54.
7
Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor.
Proc Natl Acad Sci U S A. 1985 Dec;82(24):8667-71. doi: 10.1073/pnas.82.24.8667.
8
Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance.
Science. 1986 May 23;232(4753):977-80. doi: 10.1126/science.3754653.
9
Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage.
Nature. 1986;322(6079):547-9. doi: 10.1038/322547a0.
10
Cachectin: more than a tumor necrosis factor.
N Engl J Med. 1987 Feb 12;316(7):379-85. doi: 10.1056/NEJM198702123160705.
Zotero 插件